Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2012

Global Markets Direct
November 28, 2012
44 Pages - SKU: GMD4922571


Islet Cell Carcinoma (Insulinoma) – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Islet Cell Carcinoma (Insulinoma) - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Islet Cell Carcinoma (Insulinoma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Islet Cell Carcinoma (Insulinoma). Islet Cell Carcinoma (Insulinoma) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Islet Cell Carcinoma (Insulinoma).
  • A review of the Islet Cell Carcinoma (Insulinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Islet Cell Carcinoma (Insulinoma) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Islet Cell Carcinoma (Insulinoma).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Islet Cell Carcinoma (Insulinoma) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.



More Oncology/Hematology reports by Global Markets Direct

Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2014 by Global Markets Direct
Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2014’, provides an overview ...
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014 by Global Markets Direct
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014’, provides an overview ...
Thyroid Cancer - Pipeline Review, H2 2014 by Global Markets Direct
Thyroid Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Thyroid Cancer’s therapeutic pipeline.This ...
Esophageal Cancer - Pipeline Review, H2 2014 by Global Markets Direct
Esophageal Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Esophageal Cancer - Pipeline Review, H2 2014’, provides an overview of the Esophageal Cancer’s therapeutic pipeline.This ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!